Article ID Journal Published Year Pages File Type
9112041 Diabetes Research and Clinical Practice 2005 9 Pages PDF
Abstract
We conclude that the addition of a thiazolinedione to glimepiride treatment in type 2 diabetic subjects with the metabolic syndrome is associated with a slight but significant reduction of PAI-1 value, related to a similar reduction in insulinresistance.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , , , , , , , ,